Company Profile
Dr. Reddy's Laboratories Ltd Stock Price, News & Catalysts
- Ticker:
- RDY
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- India and listed in the U
Stock performance
12.25 USD (-2.93%)
Close
Last updated: October 1, 2026
10.8B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, RDY closed down 2.93% at $12.25. No new same-company headline was identified in the current news window.
Company overview
India-Based Global Pharmaceutical Company
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in India. Its businesses include generic medicines, branded formulations, biosimilars, active pharmaceutical ingredients, pharmaceutical services, consumer health products, and selected innovative drug-development programs.
Global Generics Business
The Global Generics segment operates across North America, Europe, India, and emerging markets. It supplies oral solids, injectables, dermatology products, complex generics, and branded generics, with local commercial organizations adapting the portfolio to each market's regulatory and prescribing structure.
Branded and Consumer Health Portfolio
India and emerging markets contain substantial branded-prescription businesses, while acquired nicotine-replacement products have expanded the company's consumer-health presence. These businesses provide a different commercial model from the more price-sensitive U.S. generics market.
Pharmaceutical Services and APIs
The Pharmaceutical Services and Active Ingredients segment develops and manufactures active pharmaceutical ingredients and provides related capabilities to external customers. Vertical integration also supports selected finished-dose products and gives Dr. Reddy's experience in complex chemistry and global quality systems.
Peptides, Biosimilars, and Innovative Assets
The growth pipeline emphasizes peptides, biosimilars, and differentiated products. Programs involving semaglutide, abatacept, and other complex molecules are intended to move the company beyond conventional small-molecule generics while leveraging its development and manufacturing scale.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Dr. Reddy's Laboratories Ltd (RDY)?
Dr. Reddy's Laboratories Ltd (RDY) most recently closed at 12.25 USD, a -2.93% move versus the previous session.
What is the market cap of Dr. Reddy's Laboratories Ltd (RDY)?
Dr. Reddy's Laboratories Ltd currently has a market capitalization of 10.8B USD on BioPharmSignal.
What does Dr. Reddy's Laboratories Ltd do?
India-Based Global Pharmaceutical Company Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in India. Its businesses include generic medicines, branded formulations, biosimilars, active pharmaceutical ingredients, pharmaceutical services, consumer health products, and selected innovative drug-development programs. Global Generics...
On which exchange is RDY stock listed?
Dr. Reddy's Laboratories Ltd (RDY) is associated with NYSE, India and listed in the U, Biopharma.
What is semaglutide?
Programs involving semaglutide, abatacept, and other complex molecules are intended to move the company beyond conventional small-molecule generics while leveraging its development and manufacturing scale.
Which conditions is Dr. Reddy's Laboratories Ltd targeting with semaglutide?
Dr. Reddy's Laboratories Ltd is associated with dermatology based on its company overview and current catalyst commentary.
What is abatacept?
Programs involving semaglutide, abatacept, and other complex molecules are intended to move the company beyond conventional small-molecule generics while leveraging its development and manufacturing scale.
What is India-Based?
India-Based Global Pharmaceutical Company Dr.